Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...

The results of the lidERA trial in patients with HR-positive, HER2-negative early breast cancer – previewed last month and ...

The deal focuses on a weight-loss pill in development at YaoPharma, a GLP-1 agonist codenamed YP05002, which is currently in ...

AI-driven customer centricity is built on a continuously learning system that interprets behaviour, identifies intent, and ...

According to researchers, medical training has reached a stage where students know more, but understand less. Although there ...

If confirmed, the safety review could herald the imposition of restrictions on the use of the antibodies by HHS, which has ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

CB1 inhibition is an approach that taps into the body’s natural metabolism to burn fat while preserving muscle for more ...

The UK government has confirmed that the rebate rate for newer medicines supplied to the NHS under the Voluntary Scheme for ...

Fondazione Telethon ETS' Waskyra has become the first gene therapy in the US for patients with Wiskott-Aldrich syndrome (WAS) ...

The first CNPV approval falls into the latter category, and is for a US-manufactured version of the widely used antibiotic ...

Relation's draw is its 'lab-in-a-loop' process of AI-driven target and drug discovery, in which algorithms are used to find ...